MENU
+Compare
FOLD
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$9.81
Change
+$0.08 (+0.82%)
Capitalization
2.93B

FOLD Amicus Therapeutics Forecast, Technical & Fundamental Analysis

a developer of orally active drugs to treat human genetic diseases

Industry Biotechnology
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for FOLD with price predictions
Dec 20, 2024

FOLD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on December 13, 2024

FOLD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 48 cases where FOLD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where FOLD's RSI Oscillator exited the oversold zone, of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 20, 2024. You may want to consider a long position or call options on FOLD as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for FOLD just turned positive on December 02, 2024. Looking at past instances where FOLD's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FOLD advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 56 cases where FOLD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The 10-day moving average for FOLD crossed bearishly below the 50-day moving average on November 14, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

The 50-day moving average for FOLD moved below the 200-day moving average on November 13, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for FOLD entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FOLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.367) is normal, around the industry mean (14.529). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). FOLD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (6.017) is also within normal values, averaging (255.281).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

FOLD is expected to report earnings to fall 87.00% to 1 cents per share on February 26

Amicus Therapeutics FOLD Stock Earnings Reports
Q4'24
Est.
$0.01
Q3'24
Beat
by $0.10
Q2'24
Est.
$-0.05
Q1'24
Beat
by $0.04
Q4'23
Beat
by $0.07
The last earnings report on November 06 showed earnings per share of 10 cents, beating the estimate of 0 cents. With 4.08M shares outstanding, the current market capitalization sits at 2.93B.
A.I. Advisor
published General Information

General Information

a developer of orally active drugs to treat human genetic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
47 Hulfish Street
Phone
+1 609 662-2000
Employees
517
Web
https://www.amicusrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HWCIX28.440.35
+1.25%
Hotchkis & Wiley Disciplined Value I
VSEMX235.112.90
+1.25%
Vanguard Extended Market Index Instl Sel
JOEMX11.480.05
+0.44%
JOHCM Emerging Markets Opps Instl
IHORX18.79-0.02
-0.11%
Hartford International Opportunities R3
GQJIX9.83-0.10
-1.01%
GQG Partners Intl Qual Val Fd Ins

FOLD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+0.72%
ALDX - FOLD
46%
Loosely correlated
+0.41%
VCYT - FOLD
43%
Loosely correlated
+4.66%
RCKT - FOLD
42%
Loosely correlated
+1.85%
SRPT - FOLD
42%
Loosely correlated
-0.42%
DNLI - FOLD
41%
Loosely correlated
-0.19%
More